<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01245647</url>
  </required_header>
  <id_info>
    <org_study_id>AA018934-01-N</org_study_id>
    <secondary_id>R01AA018934-01</secondary_id>
    <nct_id>NCT01245647</nct_id>
  </id_info>
  <brief_title>Will Having Alcohol Treatment Improve Functioning?</brief_title>
  <acronym>WHAT-IF</acronym>
  <official_title>Pharmacotherapy for Hazardous Drinking in HIV Infected Women: Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to find out if a medication,naltrexone is helpful for
      HIV-infected women who sometimes drink too much. The study will try to find out whether women
      like the medication, whether the medication helps them cut back on their drinking, and
      whether it helps improve their overall health. Naltrexone has not been used widely among
      people who are engaged in less severe drinking and in primary health care settings.
      Therefore, the investigators would like to determine whether it is helpful among women who
      sometimes drink 4 or more drinks per occasion or 7 or more drinks per week. The investigators
      hypothesize that by taking naltrexone, women with hazardous drinking pattern will reduce
      their drinking which in turn will improve their medication adherence, improve their health
      and quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate the acceptability and effectiveness of a
      treatment program for hazardous drinking, delivered within HIV-clinic outpatient settings,
      that involves oral naltrexone. The central hypothesis is that women randomized to the
      treatment program will have decreased rates of hazardous drinking and improved clinical and
      behavioral health outcomes that are associated with hazardous drinking. The investigators
      have formulated this hypotheses based on the existing literature, the preliminary data and
      the clinical experience. The investigators hypothesize that women randomized to receive an
      alcohol treatment intervention will be less likely to have hazardous drinking behavior
      6-months after enrollment, compared to women who received similar assessments but no formal
      treatment intervention. The investigators hypothesize that 4-months after enrollment, women
      randomized to receive an alcohol treatment intervention will have improved adherence to HIV
      antiretroviral therapy, improved CD4 cell counts, reduced HIV viral load, and reduced risky
      sexual behavior, compared to women who receive similar assessments but no formal
      intervention.

      The investigators will recruit 90 women from 3 different sites in Florida, Washington DC and
      Chicago. Of those 90 women 60 will receive naltrexone and 30 will receive placebo. Study
      participants will take the medication for 4 months but the investigators will follow them for
      7 months. At baseline, 2 months, 4 months and 7 months, the investigators will administer
      study questionnaires and assess their liver enzymes, CD4 count and viral load. The
      investigators will also follow them up at month 1 and 3 to reinforce the medication intake
      and to assess for any possible side effects.

      New treatment options are available, but their impact on hazardous drinking has not yet been
      evaluated among HIV-infected women, many of whom are poor, minorities, or who have associated
      mental health or substance abuse problems. Delivery of therapeutic interventions must be
      improved in order to reduce hazardous drinking in women with HIV/AIDS. The proposed research
      is significant because the therapy will be offered within HIV clinic settings and will
      potentially improve the health of a population that is significantly undertreated. In
      addition to determining the effectiveness of an alcohol treatment intervention, the
      investigators will also identify key barriers and facilitators associated with adherence to
      pharmacologic treatment for alcohol in women with hazardous drinking. The findings will
      directly impact the type and quality of care for hazardous drinking in this subset of
      HIV-infected individuals and will inform both primary and secondary prevention efforts
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Drinks Per Week</measure>
    <time_frame>Month 4</time_frame>
    <description>Average number of standard alcohol drinks per week, as measured by timeline follow-back. A drink typically contains about 0.6 grams of alcohol, and generally represents 1 12-oz beer, 1 5-oz glass of wine, or one shot of liquor.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV Medication Adherence (95% or Better)</measure>
    <time_frame>Month 4</time_frame>
    <description>Medication adherence was measured on a visual analogue scale ranging from 0 - 100, and indicating what percentage of the persons' HIV medication was taken on schedule over the past week (self-report). A score of 95% or better was considered adherent, and we report the proportion of persons who were adherent in each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risky Sexual Behaviors</measure>
    <time_frame>4 months</time_frame>
    <description>Risky sexual behavior was a dichotomous outcome for each participant at each time point, defined as having any non-condom-protected sex with a males who have an unknown/negative HIV status in the previous 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV Viral Load Suppressed</measure>
    <time_frame>4 months</time_frame>
    <description>Viral load was classified as either suppressed (HIV viral load &lt;50 copies/ml) or not suppressed (HIV viral load &gt;50 copies/ml). We report the proportion of participants who had a suppressed viral load (higher number is better)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 Count (Mean)</measure>
    <time_frame>4 months</time_frame>
    <description>Results from CD4 cell count result obtained either as lab specifically for this study, or from lab results that were collected at the same time point for a different study or clinical indication.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>HIV</condition>
  <condition>Alcoholism</condition>
  <arm_group>
    <arm_group_label>Sugar Pill, 50mg, once per day for 4 months</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: One third of the participants will receive placebo pills that look the same as the active comparator but are really just inert pills. Each study participant will take a single pill once a day for 4 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naltrexone, 50mg, once per day for 4 months</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naltrexone: Two thirds of the total study participants will receive the medication naltrexone. Each study participant will take a single pill once a day for 4 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone, 50mg, once per day for 4 months</intervention_name>
    <description>Naltrexone: Two thirds of the total study participants will receive the medication naltrexone. Each study participant will take a single pill once a day for 4 months.</description>
    <arm_group_label>Naltrexone, 50mg, once per day for 4 months</arm_group_label>
    <other_name>Naltrexone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sugar pill, 50mg, once per day for 4 months</intervention_name>
    <description>Placebo: One third of the participants will receive placebo pills that look the same as the active comparator but are really just inert pills. Each study participant will take a single pill once a day for 4 months.</description>
    <arm_group_label>Sugar Pill, 50mg, once per day for 4 months</arm_group_label>
    <other_name>Inert sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hazardous drinking: defined by the NIAAA as either of the following:

               1. binge drinking (4 or more drinks per occasion at least twice monthly), (NIAAA
                  2005) - OR

               2. high quantity-frequency (&gt;7 or drinks per week)

          -  Age 18 or over

          -  Female

          -  HIV-infected documented by a rapid HIV test or any licensed ELISA test kit and
             confirmed by a repeat ELISA, Western Blot, HIV-1 culture, HIV-1 antigen, plasma HIV-1
             RNA viral load or a second antibody test by a method other than ELISA at any time
             prior to study entry.

          -  Able to understand and comply with planned study procedures.

          -  Willing and able to provide informed consent.

        Exclusion Criteria:

          -  Contraindications to treatment with naltrexone: current physiologic opiate dependence;
             current daily prescription opioid medications; positive urine drug test for opioids;
             allergic to naltrexone; significantly abnormal baseline liver enzymes (AST or ALT â‰¥ 5
             times normal); on dialysis for renal failure

          -  currently taking oral medications for tuberculosis.

          -  Currently pregnant or positive pregnancy test.

          -  currently breastfeeding.

          -  Currently taking an alcohol treatment medication (disulfiram, topiramate, naltrexone,
             acamprosate).

          -  currently homeless, unable to provide mailing address, or has plans to move from area
             within next 7 months.

          -  Unable to communicate in English.

          -  Research coordinator assessment that participant cannot comprehend the study or
             consent procedures

          -  Has current prognosis of less than 1 year to live

          -  Abnormal vital signs at enrollment visit

          -  Currently on treatment for Hepatitis C (HCV) infection

          -  Prisoner status
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert L Cook, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Women's Interagency HIV Study</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Health Science Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Interagency HIV Study</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2010</study_first_submitted>
  <study_first_submitted_qc>November 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2010</study_first_posted>
  <results_first_submitted>August 27, 2013</results_first_submitted>
  <results_first_submitted_qc>January 10, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 27, 2014</results_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>women</keyword>
  <keyword>HIV</keyword>
  <keyword>alcohol</keyword>
  <keyword>medication</keyword>
  <keyword>adherence</keyword>
  <keyword>acceptability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>We recruited participants from 3 sites in 3 cities: Washington, D.C., Chicago, and Jacksonville from December 2010 to February 2012. The last participant completed her 7-Month follow-up at October 2012.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sugar Pill, 50mg, Once a Day for 4 Months.</title>
          <description>Placebo: placebo pills looked the same as the active comparator but were really sugar pills. Each study participant in this arm took a single pill once a day for 4 months.</description>
        </group>
        <group group_id="P2">
          <title>Naltrexone, 50mg, Once a Day for 4 Months</title>
          <description>Naltrexone 50mg pills (single oral capsule): Each study participant in this arm took a single pill once a day for 4 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sugar Pill, 50mg, Once a Day for 4 Months</title>
          <description>Placebo: placebo pills looked the same as the active comparator but were really sugar pills. Each study participant in this arm took a single pill once a day for 4 months.</description>
        </group>
        <group group_id="B2">
          <title>Naltrexone, 50mg, Once a Day for 4 Months</title>
          <description>Naltrexone 50mg pills (single oral capsule): Each study participant in this arm took a single pill once a day for 4 months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.2" spread="9.3"/>
                    <measurement group_id="B2" value="48.7" spread="6.6"/>
                    <measurement group_id="B3" value="49.3" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Drinks Per Week</title>
        <description>Average number of standard alcohol drinks per week, as measured by timeline follow-back. A drink typically contains about 0.6 grams of alcohol, and generally represents 1 12-oz beer, 1 5-oz glass of wine, or one shot of liquor.</description>
        <time_frame>Month 4</time_frame>
        <population>All participants who provided data at the 4-month follow-up were included (n=15), which is 79% of persons who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill, 50mg, Once a Day for 4 Months.</title>
            <description>Placebo: placebo pills looked the same as the active comparator but were really sugar pills. Each study participant in this arm took a single pill once a day for 4 months.</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone, 50mg, Once a Day for 4 Months</title>
            <description>Naltrexone 50mg pills (single oral capsule): Each study participant in this arm took a single pill once a day for 4 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Drinks Per Week</title>
          <description>Average number of standard alcohol drinks per week, as measured by timeline follow-back. A drink typically contains about 0.6 grams of alcohol, and generally represents 1 12-oz beer, 1 5-oz glass of wine, or one shot of liquor.</description>
          <population>All participants who provided data at the 4-month follow-up were included (n=15), which is 79% of persons who were randomized.</population>
          <units>standard alcohol drinks per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="12.4" lower_limit="0.7" upper_limit="14.1"/>
                    <measurement group_id="O2" value="12.0" spread="16.5" lower_limit="-2.6" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.82</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV Medication Adherence (95% or Better)</title>
        <description>Medication adherence was measured on a visual analogue scale ranging from 0 - 100, and indicating what percentage of the persons' HIV medication was taken on schedule over the past week (self-report). A score of 95% or better was considered adherent, and we report the proportion of persons who were adherent in each group.</description>
        <time_frame>Month 4</time_frame>
        <population>Only persons who reported current HIV medication use (n=13) were considered for this outcome, and we included data from the 12 persons who completed the 4-month assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill, 50mg, Once a Day for 4 Months.</title>
            <description>Placebo: placebo pills looked the same as the active comparator but were really sugar pills. Each study participant in this arm took a single pill once a day for 4 months.</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone, 50mg, Once a Day for 4 Months</title>
            <description>Naltrexone 50mg pills (single oral capsule): Each study participant in this arm took a single pill once a day for 4 months.</description>
          </group>
        </group_list>
        <measure>
          <title>HIV Medication Adherence (95% or Better)</title>
          <description>Medication adherence was measured on a visual analogue scale ranging from 0 - 100, and indicating what percentage of the persons' HIV medication was taken on schedule over the past week (self-report). A score of 95% or better was considered adherent, and we report the proportion of persons who were adherent in each group.</description>
          <population>Only persons who reported current HIV medication use (n=13) were considered for this outcome, and we included data from the 12 persons who completed the 4-month assessment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Risky Sexual Behaviors</title>
        <description>Risky sexual behavior was a dichotomous outcome for each participant at each time point, defined as having any non-condom-protected sex with a males who have an unknown/negative HIV status in the previous 30 days.</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill, 50mg, Once a Day for 4 Months.</title>
            <description>Placebo: placebo pills looked the same as the active comparator but were really sugar pills. Each study participant in this arm took a single pill once a day for 4 months.</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone, 50mg, Once a Day for 4 Months</title>
            <description>Naltrexone 50mg pills (single oral capsule): Each study participant in this arm took a single pill once a day for 4 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Risky Sexual Behaviors</title>
          <description>Risky sexual behavior was a dichotomous outcome for each participant at each time point, defined as having any non-condom-protected sex with a males who have an unknown/negative HIV status in the previous 30 days.</description>
          <units>percentage of persons with risky sex</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.46</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV Viral Load Suppressed</title>
        <description>Viral load was classified as either suppressed (HIV viral load &lt;50 copies/ml) or not suppressed (HIV viral load &gt;50 copies/ml). We report the proportion of participants who had a suppressed viral load (higher number is better)</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill, 50mg, Once a Day for 4 Months.</title>
            <description>Placebo: placebo pills looked the same as the active comparator but were really sugar pills. Each study participant in this arm took a single pill once a day for 4 months.</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone, 50mg, Once a Day for 4 Months</title>
            <description>Naltrexone 50mg pills (single oral capsule): Each study participant in this arm took a single pill once a day for 4 months.</description>
          </group>
        </group_list>
        <measure>
          <title>HIV Viral Load Suppressed</title>
          <description>Viral load was classified as either suppressed (HIV viral load &lt;50 copies/ml) or not suppressed (HIV viral load &gt;50 copies/ml). We report the proportion of participants who had a suppressed viral load (higher number is better)</description>
          <units>percentage of persons with suppressed VL</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.12</p_value>
            <p_value_desc>no significant difference by Fisher exact test</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD4 Count (Mean)</title>
        <description>Results from CD4 cell count result obtained either as lab specifically for this study, or from lab results that were collected at the same time point for a different study or clinical indication.</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill, 50mg, Once a Day for 4 Months.</title>
            <description>Placebo: placebo pills looked the same as the active comparator but were really sugar pills. Each study participant in this arm took a single pill once a day for 4 months.</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone, 50mg, Once a Day for 4 Months</title>
            <description>Naltrexone 50mg pills (single oral capsule): Each study participant in this arm took a single pill once a day for 4 months.</description>
          </group>
        </group_list>
        <measure>
          <title>CD4 Count (Mean)</title>
          <description>Results from CD4 cell count result obtained either as lab specifically for this study, or from lab results that were collected at the same time point for a different study or clinical indication.</description>
          <units>CD4 count (cells/ml)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="669" spread="478"/>
                    <measurement group_id="O2" value="761" spread="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.67</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sugar Pill, 50 mg Once a Day for 4 Months</title>
          <description>Placebo: placebo pills looked the same as the active comparator but were really sugar pills. Each study participant in this arm took a single pill once a day for 4 months.</description>
        </group>
        <group group_id="E2">
          <title>Naltrexone, 50mg Pill Once a Day for 4 Months</title>
          <description>Naltrexone 50mg pills (single oral capsule): Each study participant in this arm took a single pill once a day for 4 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasm/diarrhea/anxiety</sub_title>
                <description>muscle spasms every few minutes, diarrhea, urinary incontinence, anxiety, restlessness and SOB. Was admitted for observation 4-20-11 and discharged 4-22-11. The ER Physician remarked that it was not likely due to naltrexone.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea/upset stomach</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sleepiness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Sample size was very small, and 3 participants did not return for any follow-up visits; 15 completed through the Month 4 assessment, and 12 completed through Month 7. Therefore, our ability to draw conclusions based on this sample is limited.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Bob Cook</name_or_title>
      <organization>University of Florida</organization>
      <phone>352-273-5869</phone>
      <email>cookrl@ufl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

